Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > BIOIDENT Receives 2007 Frost & Sullivan Enabling Technology of the Year Award

Abstract:
Company's PhotonicLab Platform Recognized by Prominent Analyst Firm

BIOIDENT Receives 2007 Frost & Sullivan Enabling Technology of the Year Award

MENLO PARK, CA | Posted on May 8th, 2007

BIOIDENT Technologies Inc., the leading company in the development of printed optoelectronic solutions for life sciences, today announced that it is the recipient of the 2007 Frost & Sullivan Enabling Technology of the Year Award for its superior expertise in lab-on-a-chip technologies.

The distinguished award is presented to a company who has developed a solution that revolutionizes an industry and removes a significant stumbling block in the development of a technology. The award criteria also ensure that the enabling technology translates into a more efficient, cost-effective and portable alternative for end-users.

"We are honored to be chosen for this prestigious award that recognizes our revolutionary, disposable lab-on-a-chip platform, which sets new standards in the industry," said Dr. Wasiq Bokhari, CEO for BIOIDENT. "This acknowledgment validates BIOIDENT's expertise in integrating microfluidics and organic photonics into a single solution and exemplifies the wide ranging capabilities of the technology in applications such as point-of-care diagnostics, water and food analysis, and chemical and biological agent detection."

BIOIDENT utilizes breakthroughs in science and nanotechnology to develop printed optoelectronic solutions that take lab-on-a-chip devices to the next level by integrating an optoelectronic readout system into the chip. The company uses established testing protocols to deliver real-time and in-situ multi-parameter detection capabilities for all categories of chemical and biological analytes, which expands its applications.

"BIOIDENT's pioneering technology will transform the point-of-care-testing (POCT) and life science industry, especially as manufacturers seek devices that are user-friendly, provide superior test results and are available at a competitive price," explains Arun AK, analyst for Frost & Sullivan. "With the company's deep expertise, rapid production capability and innovative applications, BIOIDENT is poised to become a global leader in providing safe, breakthrough health care products."

For more information about BIOIDENT, the PhotonicLab™ Platform and PhotonicFlow™ System, please visit http://www.bioident.com .

####

About BIOIDENT Technologies Inc.
BIOIDENT is the technology leader in the development of printed semiconductor-based photonic lab-on-a-chip solutions for the life science market. The company’s core technology utilizes the latest breakthroughs in science and nanotechnology to create the PhotonicLab™ Platform. This platform is used to produce the world’s first disposable photonic lab-on-a-chip solutions for next generation mobile analytics applications such as water and food analysis, chemical and biological agent detection, and personal or in-the-field diagnostics.

BIOIDENT is a subsidiary of Austrian-based NANOIDENT Technologies AG.

The company is privately-held with headquarters in Menlo Park, Calif. BIOIDENT leverages NANOIDENT’s SEMICONDUCTOR 2.0™ Platform technology and its high-speed manufacturing process, which uses liquid conductive and semi-conductive materials to print electronic circuits on almost any surface using an inkjet printer.

For more information, please click here

Contacts:
Schwartz Communications
Alissa Vasilevskis or Carmen Pearson, +1-415-512-0770

or
BIOIDENT Technologies Inc.
+1-650-391-4248

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

From champagne bubbles, dance parties and disease to new nanomaterials: Understanding nucleation of protein filaments might help with Alzheimer's Disease and type 2 Diabetes November 24th, 2016

Nanopolymer-modified protein array can pinpoint hard-to-find cancer biomarker November 17th, 2016

Nanotechnology Treatment Found to Inhibit Mesothelioma Tumor Growth November 16th, 2016

Announcements

Research Study: MetaSOLTM Shatters Solar Panel Efficiency Forecasts with Innovative New Coating: Coating Provides 1.2 Percent Absolute Enhancement to Triple Junction Solar Cells December 2nd, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Quantum obstacle course changes material from superconductor to insulator December 1st, 2016

Throwing new light on printed organic solar cells December 1st, 2016

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

Quantum obstacle course changes material from superconductor to insulator December 1st, 2016

'Back to the Future' inspires solar nanotech-powered clothing November 15th, 2016

2-D material a brittle surprise: Rice University researchers finds molybdenum diselenide not as strong as they thought November 14th, 2016

New Book by Nobel Laureate Tells Story of Chemistry’s New Field: Fraser Stoddart explains the mechanical bond and where it is taking scientists November 11th, 2016

Nanobiotechnology

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

From champagne bubbles, dance parties and disease to new nanomaterials: Understanding nucleation of protein filaments might help with Alzheimer's Disease and type 2 Diabetes November 24th, 2016

Making spintronic neurons sing in unison November 18th, 2016

Photonics/Optics/Lasers

Controlled electron pulses November 30th, 2016

New method for analyzing crystal structure: Exotic materials called photonic crystals reveal their internal characteristics with new method November 30th, 2016

Novel silicon etching technique crafts 3-D gradient refractive index micro-optics November 28th, 2016

Single photon converter -- a key component of quantum internet November 28th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project